Background
==========

Hepatocellular carcinoma (HCC) is a highly aggressive solid tumor associated with poor prognosis \[[@B1]\]. Curative therapies of surgical treatment, including hepatic resection and liver transplantation, improve the chances of survival of patients with HCC \[[@B2]-[@B4]\]. However, a limited number of patients can be treated with surgery because of the damage to liver function. The prognosis for most patients remains poor after surgery for multicentric recurrence and intrahepatic metastasis \[[@B5],[@B6]\]. Therefore, the development of a systemic therapy that targets a new molecule involved in HCC is needed.

Fibroblast growth factor (FGF) signaling plays an important role in a variety of processes, including proliferation, cellular differentiation, wound repair, and angiogenesis \[[@B7]-[@B9]\]. It has been reported that amplification or overexpression of FGFs is associated with the pathogenesis of malignant neoplasms, such as leukemias and sarcomas as well as stomach, pancreas, bladder, colon, breast, and prostate cancer \[[@B10]-[@B15]\]. Further, several correlations between overexpression, polymorphism, translocation, and truncation of FGF receptor (FGFR) and a variety of human neoplasms such as myeloma, breast, stomach, colon, bladder, and cervical cancer have also been reported \[[@B16]-[@B21]\]. Therefore, the FGF/FGFR system plays a critical role in tumor progression.

FGF19 was first identified on the basis of its amino acid similarities to murine FGF15 (53% identity) \[[@B22]\]. FGF19 is currently unique in displaying apparent specificity for FGFR4 \[[@B23],[@B24]\]. Previous studies have reported that FGF19 and hepatocyte FGFR4 regulate biosynthesis in the bile duct by repression of *CYP7A1*\[[@B25]\]. Further, FGF19 reportedly increases the metabolic rate, reduces body weight, and reverses diabetes in both high-fat-fed mice and leptin-deficient mice \[[@B26]\]. On the other hand, ectopic expression of FGF19 in mice promotes hepatocyte proliferation, hepatocellular dysplasia, and neoplasia \[[@B27]\]. Moreover, recent reports have revealed that a neutralizing antibody that selectively blocks the interaction of FGF19 with FGFR4 inhibits the growth of colon tumors and the formation of liver tumors *in vivo*\[[@B28]\]. However, although the involvement of FGF19 in HCC has been demonstrated, no study has so far addressed the significance of FGF19 expression or clarified its role in the mechanism of HCC development in humans \[[@B29]\].

In this study, we hypothesized that the FGF19/FGFR4 system is activated in patients with HCC and is correlated with the aggressiveness of the tumor. We elucidated the association between the FGF19/FGFR4 system and the development of HCC using human samples and *in vitro*experimental models.

Methods
=======

Patients and specimens
----------------------

Cancerous tissues and surrounding non-cancerous hepatic parenchyma were obtained from 40 primary HCC Japanese patients who underwent curative resection surgery at Chiba University Hospital, Japan, from January 1995 to December 2001. They did not have any other malignancies. The ethics committee of Chiba University Hospital approved this study. Informed consent was obtained from every patient for the use of resected tissue before the study began. Samples were obtained from 31 men and 9 women aged 49-78 years. Specimens were histologically classified by the Japanese staging system of the Liver Cancer Study Group of Japan \[[@B30]\]. In the corresponding noncancerous parenchyma, cirrhosis was found in 14 patients (35%).

Cells
-----

The human HCC cell lines HuH7, HepG2, HLE, HLF, PLC/PRF/5, JHH1, JHH2, JHH5, JHH6, and JHH7 were obtained from the Health Science Research Resources Bank (Osaka, Japan). HuH7, HepG2, HLE, HLF, and PLC/PRF/5 were cultured in Dulbecco\'s Modified Eagle\'s Medium containing 10% fetal bovine serum (Sigma-Aldrich Corp., St. Louis, MO). JHH1, JHH2, JHH5, JHH6, and JHH7 were cultured in William\'s Medium E with 10% fetal bovine serum. Primary cultures of human hepatocytes were prepared and cultured as described in previous papers \[[@B31]\].

RNA extraction and cDNA synthesis
---------------------------------

Total RNA from the cell lines and tissues was isolated using RNeasy Mini Kits (Qiagen, Hilden, Germany) according to the manufacturer\'s protocol. Specimens were taken from viable and non-fibrotic areas of tumors and noncancerous tissues. They were quickly frozen in liquid nitrogen and then stored at -80°C until use. Synthesis of cDNA from total RNA was conducted using a Ready-to-Go^®^cDNA synthesis kit (Amersham Biosciences Corp., Piscataway, NJ) following the manufacturer\'s protocols.

Real-time quantitative RT-PCR analysis
--------------------------------------

The expressions of *FGF19*and *FGFR4*were examined by reverse transcription polymerase chain reaction (RT-PCR) with the following primers: (forward) (5\'-TCT CCT CTG ACT TCA ACA GCG ACA C-3\') and (reverse) (5\'-TGT TGC TGT AGC CAA ATT CGT TGT C-3\') for human GAPDH, (forward) (5\'-CAG CTG TAC AAG AAC AGA GGC TTT C-3\') and (reverse) (5\'-AAA TGG GTC CAT GCT GTC GGT CTC C-3\') for FGF19, and (forward) (5\'-CAT CCG CTG GCT TAA GGA TGG AC-3\') and (reverse) (5\'-ATC ACG AGA CTC CAG TGC TGA TG-3\') for FGFR4. All PCR reactions were performed using the SYBR Green PCR Core Reagents kit (Perkin-Elmer Applied Biosystems, Foster City, CA, USA) under the following conditions: 1 cycle at 95°C for 10 min, 50 cycles at 95°C for 10 sec, 60°C for 5 sec, 72°C for 10 sec, and 80°C for 1 sec. Real-time detection of the SYBR Green emission intensity was conducted with a LightCycler^®^(Roche, Mannheim, Germany). An equivalent amount of cDNA sample, derived from 40 ng total RNA, was used for each PCR reaction. The mRNA in each sample was then automatically quantified with reference to the standard curve constructed with each use of the LightCycler^®^. Quantitative RT-PCR was performed at least three times per sample. To standardize the amount of RNA, we quantified the expression of *GAPDH*mRNA in each sample and then divided the amounts of expressed *FGF19*and *FGFR4*mRNA by that of *GAPDH*.

Immunohistochemical staining
----------------------------

An immunohistochemical analysis was performed on paraffin-embedded sections using the Envision kit (Dako, Glostrup, Denmark) following the manufacturer\'s instructions. The sections were boiled in retrieval solution to expose antigens. Anti-FGF19 (R&D Systems, Inc., MN) monoclonal antibodies, anti-FGFR4 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) monoclonal antibodies and control antibody (R&D Systems, Inc., MN) were applied as the primary antibodies to the sections at a dilution of 25 μg/mL and 1:50. The section slides were counterstained with hematoxylin, dehydrated, and mounted. The immunostaining was evaluated independently by two pathologists.

Cell fixation and staining
--------------------------

HuH7, HepG2, HLE, HLF, and JHH7 cells (1 × 10^4^/well) were seeded and cultured at 37°C in a humidified 5% CO~2~atmosphere for 24 h. Then, the cells were washed 3 times with phosphate-buffered saline (PBS) and fixed in 100% acetone for 10 min at 4°C. After fixation, cells were washed 3 times with PBS. Cells were blocked in blocking serum at room temperature for 1 h in a humidified chamber. Cells were washed 3 times with PBS and stained at the same dilution as paraffin-embedded sections.

Cell proliferation assay with FGF19 recombinant protein
-------------------------------------------------------

Cells were seeded (6 × 10^3^/well) with FGF19 recombinant protein (Cell Sciences, MA, USA) at concentrations of 0.1, 1, 10, or 100 ng/mL and cultured. After 48, 72, or 96 h, 20 μL of Cell Titer 96^®^AQ~ueous~(Promega, WI, USA) was added to the culture media then incubated for 1 h at 37°C in a humidified 5% CO~2~atmosphere. Then, the absorbance of each of the plates at 490 nm was recorded using a 96-well plate reader (Bio-Rad, CA, USA). The proliferation index (PI) was defined as OD values of the recombinant protein-treated cells divided by those of the untreated control cells. We examined proliferation assay with 12 chambers in the same condition at the same time.

Cell apoptosis assay with FGF19 recombinant protein
---------------------------------------------------

Cells were harvested at 48 h after seeding and incubation with 1 ng/ml of FGF19 recombinant protein. To initiate apoptosis, 5-fluorouracil (5-FU) (Roche) was added at a final concentration of 10 μg/mL. After further incubation and gravity sedimentation for 24 h, the supernatant was removed carefully and the cell pellets were resuspended in 200 μL lysis buffer. Then, ELISA was performed using the Cell Death Detection Kit (Roche) according to the manufacturer\'s specifications. The apoptosis index (AI) was defined as OD values of recombinant protein-treated cells divided by those of the controls. We examined apoptosis assay with 12 chambers in the same condition at the same time.

Invasion assay with FGF19 recombinant protein
---------------------------------------------

Double-chamber transwell plates with 8-μm pore-size polycarbonate membrane inserts at the base of the upper chamber (Cell Biolabs, Inc., San Diego, CA) were used. Here, 300 μL of warm, serum-free media was added to each upper chamber and incubated for 1 h at 37°C. Upper chambers containing the reconstituted Matrigel membranes were set into the lower chambers of the 24-well cluster plates. JHH7 cells were trypsinized, counted, and resuspended with fresh medium before being plated into the upper chambers of the assay wells. Approximately 1 × 10^6^cells were plated in 300 μL of defined medium into each upper chamber. Then, 500 μL of medium was added to each lower chamber. Both the media in the upper and lower chambers contained 1 ng/ml of human recombinant FGF19. JHH7 were cultured in this way for 48 h in a humidified 5% CO~2~atmosphere. The medium in the upper chamber was then aspirated, and cells from its inner surface were wiped off using a cotton swab. The membranes were stained with 400 μL of Cell Stain Solution and incubated for 10 min at room temperature. Stained inserts were gently washed several times with water. Then, the stained inserts were transferred to an empty well containing 200 μL of extraction solution and incubated for 10 min on an orbital shaker. Subsequently, 100 μL from each sample was transferred to a 96-well microtiter plate, and the OD 560 nm of each sample was measured in a 96-well plate reader (Bio-Rad, Hercules, CA). We examined invasion assay with 6 chambers in the same condition at the same time.

Migration assay with FGF19 recombinant protein
----------------------------------------------

Migration assay was performed by using transwell plates with 8 μm pore (BD Biosciences). JHH7 cells (1 × 10^5^) suspended in 500 μl serum-free Williams medium were seeded into the upper part, whereas the lower compartment was filled with 1 ml medium with 1 ng/ml of the human FGF19 recombinant protein. After incubation for 24 h at 37°C in 5% CO~2~, non-migrating cells were removed from the upper surface of the membrane by scrub. Cells on the reverse side were stained with 0.1% crystal violet, and counted under a microscope at x100 magnification. We examined migration assay with 6 chambers in the same condition at the same time.

Gene knockdown using small interfering RNA transfection
-------------------------------------------------------

Transfections of *FGF19, FGFR4*and non-targeting negative control small interfering RNA (siRNA) (AMBION, Austin, TX) were conducted with Lipofectamine 2000 (Invitrogen, Carlsbad, CA) in 96-well plates according to the manufacturer\'s specifications. The day before transfection, the JHH7 cells were trypsinized, counted, and seeded at 6 × 10^3^cells per well into 96-well plates. Lipofectamine 2000 diluted in Opti-MEM (Invitrogen) was supplemented to the siRNA mixture. The mixture was incubated for 20 min at room temperature. The mixture and Opti-MEM were added to the plate to a final siRNA concentration of 20 nM.

Flow cytometry
--------------

Control and *FGFR4*-specific siRNA were transfected into JHH7 as described above. At 72 h after transfection, the cells were collected and stained with either a phycoerythrin-conjugated anti-FGFR4 antibody (BioLegend, San Diego, CA) or an isotype-matched control (R&D systems, Minneapolis, MN). Flow cytometric analysis of cell surface FGFR4 was performed using a FACSCalibur analyzer (Becton Dickinson Immunocytometry Systems, San Jose, CA).

Cell proliferation assay after FGF19 and FGFR4 siRNA transfection
-----------------------------------------------------------------

Cells (6 × 10^3^per well) were seeded into 96-well plates, cultured for 24 h, and transfected with control, *FGF19*, or *FGFR4*siRNA. At 72 h after transfection, cells were harvested. Then, 20 μL of Cell Titer 96^®^AQ~ueous~(Promega) was added to the culture media and incubated for 2 h at 37°C in a humidified 5% CO~2~atmosphere. The absorbance of the plates at 490 nm was recorded using a 96-well plate reader (Bio-Rad).

Apoptosis assay after FGF19 and FGFR4 siRNA transfection
--------------------------------------------------------

Cells (6 × 10^3^per well) were seeded into 96-well plates, cultured for 24 h, and transfected with control, *FGF19*, or *FGFR4*siRNA. Cells were harvested at 72 h after transfection. To initiate apoptosis, 5-FU (Roche) at a final concentration of 10 μg/mL was added. After further incubation and gravity sedimentation for 24 h, the supernatant was carefully removed, and the cell pellets were resuspended in 200 μL lysis buffer. Then, ELISA was performed using the Cell Death Detection Kit (Cell Biolabs, Inc.) according to the manufacturer\'s specifications.

Changes in serum FGF19 levels in patients with HCC after hepatectomy
--------------------------------------------------------------------

Blood serum was obtained from 10 healthy subject and 29 primary HCC patients who underwent curative resection at Chiba University Hospital, Japan, from 2005 to 2007 (22 men, 7 women). The samples were obtained on the day before and the day after surgery. A sandwich ELISA kit was used for colorimetric detection of FGF19 in serum (FGF19 Quantikine ELISA kit, Minneapolis, MN) following the manufacturer\'s instructions.

Statistical analysis
--------------------

The relative mRNA expression levels (*FGF19/GAPDH*and *FGFR4/GAPDH*) were calculated from the quantified data. Mann-Whitney\'s *U*test was used to analyze the differences in the *FGF19*and *FGFR4*expression levels between HCCs and the corresponding noncancerous hepatic tissues. To analyze the correlation between *FGF19, FGFR4*, and clinicopathological parameters, differences in the numerical data between the two groups were evaluated using the Kruskal-Wallis test. Overall and disease-free survival rates were then calculated using the Kaplan-Meier method, and the differences in survival curves were analyzed using the log-rank test. Survival was counted if the patient was still alive or had died of other causes. Independent prognostic factors were analyzed by the Cox proportional hazards regression model in a stepwise manner. All the statistical analyses were performed using Stat View software (Version 5.0, Abacus Concepts, Berkeley, CA). Data are expressed as mean ± SE. *P*\< 0.05 denoted the presence of a statistically significant difference.

Results
=======

FGF19 and FGFR4 expression in HCC
---------------------------------

We examined 40 HCC samples and corresponding noncancerous hepatic tissues for *FGF19*mRNA expression using real-time quantitative RT-PCR. The average *FGF19/GAPDH*level in HCCs was significantly higher than that in noncancerous tissues. (Figure [1](#F1){ref-type="fig"}A; *P*= 0.015), whereas *FGFR4*was not significantly overexpressed in HCCs compared to noncancerous tissues (Figure [1](#F1){ref-type="fig"}B, *P*= 0.055). An immunohistochemical study using anti-FGF19 monoclonal antibodies was performed to determine whether FGF19 protein was expressed in HCC specimens. FGF19 protein was detectable in both cancer and noncancerous tissues Figure [1](#F1){ref-type="fig"}C). FGF19 staining was observed in the cytoplasm of tumor cells and noncancerous hepatocytes, and tended to be greater in the tumor cells. FGFR4 staining was not significantly greater in the membranes of tumor cells as compared to those of cells from corresponding noncancerous tissue (Figure [1](#F1){ref-type="fig"}D).

![**Real-time quantitative RT-PCR analysis, immunohistochemical staining of representative specimens from HCC patients of 40 HCC samples**. (**A**): Ratio of average *FGF19/GAPDH*expression in HCC (T) compared with corresponding noncancerous hepatic tissues (N). The average *FGF19/GAPDH*level in HCCs. (**B**): The average *FGFR4/GAPDH*level in HCCs. (**C**): Immunohistochemistry using anti-FGF19 monoclonal antibodies; HCC tissue (lower) and noncancerous hepatocytes (upper). (**D**): Immunohistochemistry using anti-FGFR4 monoclonal antibodies; HCC tissue (lower) and noncancerous tissue (upper). (Original magnifications: ×40 (upper); ×40 (lower)). RT-PCR; reverse transcription polymerase chain reaction; HCC, hepatocellular carcinoma.](1471-2407-12-56-1){#F1}

Correlation between FGF19 mRNA expression and clinicopathological parameters in HCC
-----------------------------------------------------------------------------------

The correlation between *FGF19*expression and clinicopathological parameters in patients with HCC is shown in Table [1](#T1){ref-type="table"}. Significant correlation was found only between *FGF19*mRNA expression and pathological stage. (Table [1](#T1){ref-type="table"}, *P*= 0.049).

###### 

Correlations between *FGF19*expression and clinicopathological parameters in 40 patients with HCC

  Clinicopathological parameters   Patient number   Tumor *FGF19*mRNA\* (Mean ± SE)   *P*value
  -------------------------------- ---------------- --------------------------------- ---------------
  Age                                                                                 
   \< 65 years                     23               0.007 ± 0.006                     0.505
   ≥65 years                       17               0.016 ± 0.014                     
  Gender                                                                              
   Male                            31               0.014 ± 0.009                     0.319
   Female                          9                0.003 ± 0.002                     
  Virus                                                                               
   HBV                             4                0.058 ± 0.058                     0.808
   HCV                             27               0.002 ± 0.001                     
   None                            9                0.017 ± 0.016                     
  Miran Criteria                                                                      
   In                              17               0.001 ± 0.000                     0.194
   Out                             23               0.0019 ± 0.011                    
  AFP                                                                                 
   \< 10 ng/mL                     20               0.013 ± 0.012                     0.194
   ≥ 10 ng/mL                      20               0.009 ± 0.007                     
  Tumor size                                                                          
   \< 5 cm                         20               0.001 ± 0.000                     0.137
   ≥5 cm                           20               0.021 ± 0.013                     
  Histologic type of tumor                                                            
   Well differentiated             6                0.001 ± 0.001                     0.808
   Moderately differentiated       31               0.014 ± 0.009                     
   Poorly differentiated           3                0.002 ± 0.001                     
  Formation of fibrous capsule                                                        
   Present                         39               0.011 ± 0.007                     \-\-\-\-\-\--
   Absent                          1                0.0002                            
  Capsular infiltration                                                               
   Present                         38               0.012 ± 0.007                     0.718
   Absent                          2                0.0003 ± 0.0003                   
  Septal formation                                                                    
   Present                         30               0.014 ± 0.009                     0.445
   Absent                          10               0.002 ± 0.002                     
  Serosal invasion                                                                    
   Present                         1                0.016                             \-\-\-\-\-\--
   Absent                          39               0.011 ± 0.007                     
  Portal invasion                                                                     
   Present                         30               0.014 ± 0.009                     0.449
   Absent                          10               0.002 ± 0.002                     
  Hepatic vein invasion                                                               
   Present                         10               0.024 ± 0.023                     0.269
   Absent                          30               0.007 ± 0.005                     
  Intrahepatic metastasis                                                             0.580
   Present                         22               0.008 ± 0.006                     
   Absent                          18               0.015 ± 0.013                     
  Bile duct invasion                                                                  
   Present                         1                0.232                             \-\-\-\-\-\--
   Absent                          39               0.005 ± 0.004                     
  Lymph node metastasis                                                               
   Present                         1                0.001                             \-\-\-\-\-\--
   Absent                          39               0.011 ± 0.007                     
  Pathological stage                                                                  
   II                              7                0.0004 ± 0.0002                   0.049
   III                             14               0.020 ± 0.016                     
   IV                              19               0.009 ± 0.007                     

*HBV*hepatitis B virus, *HCV*hepatitis C virus, *AFP*alpha-fetoprotein, *S.E*. standard error

Univariate and multivariate analysis of prognostic factors for patients with HCC
--------------------------------------------------------------------------------

For statistical analysis of *FGF19*levels, the specimens were divided into two groups based on the median value of tumor *FGF19*mRNA (5.7 × 10^-4^): a high expression group (n = 20) and a low expression group (n = 20). We analyzed disease-free survival rates and overall survival rates to assess the prognostic significance of *FGF19*. The 5-year disease-free and overall survival rates of the 40 patients with HCC were 10% and 40%, respectively. Using the Kaplan-Meier curve assessment, we found that patients with higher FGF19 expression levels had lower 5-year survival rates than patients with lower FGF19 expression levels (disease-free survival rate, 0% vs. 20%; *P*= 0.0061; overall survival rate, 20% vs. 60%; *P*= 0.0046; as shown in Figure [2](#F2){ref-type="fig"}). To evaluate the potential of using FGF19 expression in determining the postoperative prognosis of HCC patients, univariate analysis using a Cox proportional hazard regression model was conducted (Table [2](#T2){ref-type="table"}). The results showed that the serum AFP index, *FGF19*mRNA level, and intrahepatic metastasis were significant predictors of disease-free survival (*P*= 0.004, 0.021, and 0.020, respectively), while Milan criteria, serum AFP index, *FGF19*mRNA level, tumor size, and intrahepatic metastasis were significant predictors of overall survival (*P*= 0.006, 0.042, 0.018, 0.028 and 0.020, respectively). Multivariate analysis was conducted with 5 prime variables that are regarded as prognostic factors for patients with HCC in previous studies because of the small sample size of patients (Table [3](#T3){ref-type="table"})\[[@B30]\]. A high *FGF19*mRNA level remained significant in both disease-free survival and overall survival, and was the strongest in overall survival (*P*= 0.040 and 0.003, odds ratio = 2.34 and 3.61, respectively).

![**Survival rates of 40 patients with HCC**. (**A**) Disease-free survival rates of patients with HCCs. (**B**) Overall survival rates of patients with HCCs. High expression of *FGF19*mRNA was significantly associated with poorer prognosis.](1471-2407-12-56-2){#F2}

###### 

Univariate analysis of disease-free and overall patient survivals with hepatocellular carcinoma

  Clinicopathological Parameters   Median Disease-free survival   *P*value        Median Overall survival   *P*value
  -------------------------------- ------------------------------ --------------- ------------------------- ---------------
  Age                                                                                                       
   \< 65 years                     237                            0.349           1267                      0.673
   ≥ 65 years                      594                                            1234                      
  Gender                                                                                                    
   Male                            673                            0.079           1283                      0.568
   Female                          283                                            1092                      
  Virus                                                                                                     
   HBV                             237                            0.178           1211                      0.968
   HCV                             325                                            1283                      
   None                            847                                            1234                      
  Miran Criteria                                                                                            
   In                              847                            0.061           1940                      0.006
   Out                             256                                            572                       
  AFP                                                                                                       
   High (n = 20)                   237                            0.004           573                       0.042
   \> 10 ng/mL                                                                                              
   Low (n = 20)                    847                                            1818                      
   ≤ 10 ng/mL                                                                                               
  FGF19T                                                                                                    
   High (n = 20)                   283                            0.021           628                       0.018
   Low (n = 20)                    413                                            1758                      
  Tumor size                                                                                                
   \< 5 cm                         717                            0.171           1428                      0.028
   ≥ 5 cm                          256                                            498                       
  Histologic type of tumor                                                                                  
   Well differentiated             673                            0.813           1428                      0.712
   Moderately differentiated       323                                            1234                      
   Poorly differentiated           594                                            1092                      
  Formation of fibrous capsule                                                                              
   Present                         413                            \-\-\-\-\-\--   1267                      \-\-\-\-\-\--
   Absent                          64                                             64                        
  Capsular infiltration                                                                                     
   Present                         403                            0.853           1234                      0.725
   Absent                          64                                             64                        
  Septal formation                                                                                          
   Present                         325                            0.872           1230                      0.777
   Absent                          413                                            1283                      
  Serosal invasion                                                                                          
   Present                         104                            \-\-\-\-\-\--   172                       \-\-\-\-\-\--
   Absent                          413                                            1267                      
  Portal invasion                                                                                           
   Present                         283                                            825                       0.105
   Absent                          881                                            1940                      
  Hepatic vein invasion                                                                                     
   Present                         256                            0.215           573                       0.150
   Absent                          597                                            1428                      
  Intrahepatic metastasis                                                                                   
   Present                         283                            0.020           628                       0.020
   Absent                          881                                            1983                      
  Bile duct invasion                                                                                        
   Present                         403                            \-\-\-\-\-\--   1267                      \-\-\-\-\-\--
   Absent                          413                                            573                       
  Lymph node metastasis                                                                                     
   Present                         256                            \-\-\-\-\-\--   347                       \-\-\-\-\-\--
   Absent                          413                                            1267                      
  Pathological stage                                                                                        
   II                              1373                           \-\-\-\-\-\--   2085                      0.060
   III                             594                                            1234                      
   IV                              237                                            572                       

*HBV*hepatitis B virus, *HCV*hepatitis C virus, *AFP*alpha-fetoprotein

###### 

Multivariate analysis of disease-free and overall patient survivals with hepatocellular carcinoma

  Variable                    Disease-free survival   Overall survival                              
  --------------------------- ----------------------- ------------------ ------- ------ ----------- -------
  Portal invasion (0-4)       2.59                    1.27-5.28          0.009   2.74   1.31-5.73   0.007
  AFP                         2.49                    1.09-5.72          0.031   2.03   0.84-4.91   0.114
  (≤ 10 ng/mL: \> 10 ng/mL)                                                                         
  Tumor size                  0.58                    0.14-2.35          0.445   0.87   0.21-3.56   0.845
  (≤ 5 cm: \> 5 cm)                                                                                 
  Intrahepatic metastasis     1.25                    0.60-2.60          0.550   1.53   0.66-3.53   0.319
  (absent: present)                                                                                 
  Miran criteria              0.31                    0.76-1.27          0.105   0.28   0.07-1.19   0.085
  (in: out)                                                                                         
  tumor FGF19                 2.34                    1.04-5.26          0.040   3.61   1.56-8.36   0.003
  (high: low)                                                                                       

*AFP*alpha-fetoprotein, *C.I*. confidence interval

FGF19 expression of the HCC cell lines
--------------------------------------

We used RT-PCR to analyze the differential expression of *FGF19*by measuring mRNA levels among 10 HCC lines. *FGF19*mRNA was expressed in all HCC lines, and at a remarkably higher level in JHH7 (Figure [3](#F3){ref-type="fig"}A). FGF19 protein was detected using an FGF19 ELISA kit in culture media for all human HCC lines and normal hepatocyte at 72 h after seeding; FGF19 was noted to be significantly higher in JHH7 cells and significantly lower in normal hepatocyte (Figure [3](#F3){ref-type="fig"}B). An immunocytohistochemical study using anti-FGF19 monoclonal antibodies was performed to determine whether FGF19 is expressed in all HCC lines; FGF19 protein was detectable in all HCC lines in the cytoplasm (Figure [3](#F3){ref-type="fig"}C). Similarly, *FGFR4*mRNA was expressed in all HCC lines (Figure [3](#F3){ref-type="fig"}D). Through FGFR4 staining, FGFR4 protein was observed in all HCC lines (Figure [3](#F3){ref-type="fig"}E).

![**(A) *FGF19*mRNA expression in cell extracts from HuH7, HepG2, PLC/PRF/5, HLE, HLF, JHH1, JHH2, JHH5, JHH6, and JHH7 cell lines was examined using quantitative RT-PCR (*n*= 8)**. *FGF19*was expressed in all cell lines. (**B**) FGF19 protein levels in the supernatant media from ten cell lines and normal hepatocytes (normal HC) were assayed by ELISA. FGF19 was detected in the supernatant of all of them. (**C**) Using anti-FGF19 monoclonal antibodies, diffuse positive staining was demonstrated in the cytoplasm of HuH7, HepG2, HLE, HLF, and JHH7 cells. The closed rectangles indicate the same cells stained Immunohistochemically using control antibody. (**D**) *FGFR4*mRNA expression in cell extracts from HuH7, HepG2, PLC/PRF/5, HLE, HLF, JHH1, JHH2, JHH5, JHH6, and JHH7 cell lines was examined using quantitative RT-PCR (*n*= 8). *FGFR4*was expressed in all cell lines. (**E**) Using anti-FGFR4 monoclonal antibodies, positive staining was demonstrated in the cell membranes of all of the above HCC lines. (Original magnifications (**C**) × 400), (**E**) × 400)) The closed rectangles indicate the same cells stained Immunohistochemically using control antibody.](1471-2407-12-56-3){#F3}

Proliferation, apoptosis assay, invasion, and migration assay with FGF19 recombinant protein
--------------------------------------------------------------------------------------------

We chose the HuH7, HepG2, HLE, HLF, and JHH7 cell lines upon consideration of the combination of FGF19 and FGFR4 levels. We cultured these HCC lines with FGF19 recombinant protein at concentrations of 0.01, 0.1, 0.5, 1, 5, 10, 50, or 100 ng/mL and performed a proliferation assay (Figure [4](#F4){ref-type="fig"}A; *n*= 12, *P*\< 0.05). We found that the proliferation of all HCC cells examined increased significantly upon addition of FGF19 recombinant protein at concentrations of 0.01-10 ng/mL over 48-96 h (Figure [4](#F4){ref-type="fig"}B). The proliferation index was highest when the concentration of FGF19 was 1 ng/mL in the 5 HCC lines, whereas apoptosis of HCC cells was significantly suppressed by addition of 1 ng/mL FGF19 recombinant protein in culture media (Figure [5](#F5){ref-type="fig"}A; *n*= 12, *P*\< 0.05). Tumor metastasis is still a major problem in management of cancer. In order to investigate further whether FGF19 plays an important role in tumor metastasis, the invasion assay and migration assay were performed. Invasion assays were used to investigate the alteration of cancer cell invasiveness in the presence of FGF19 recombinant protein for JHH7. The assays were conducted by staining and measuring the OD at 560 nm; they revealed that 1 ng/mL of the FGF19 recombinant protein significantly increased the mobility and invasiveness of the JHH7 cells (Figure [5](#F5){ref-type="fig"}B; *n*= 6, *P*\< 0.05). As shown in Figure [5](#F5){ref-type="fig"}C, the number of migrated cells also increased dramatically after addition of the FGF19 recombinant protein (Figure [5](#F5){ref-type="fig"}C; *n*= 6, *P*\< 0.05). Results of the invasion assay and migration assay indicate that FGF19 may be an activator of tumor metastasis.

![**(A) Proliferation changes after addition of various concentration of the FGF19 recombinant protein**. (**B**) The proliferation index (PI) was defined as the OD values of cells treated with recombinant protein divided by those of untreated cells. The PI increased after addition of FGF19 recombinant protein (0.01-10 ng/mL final concentration) to culture media and culturing for 96 h. PI, proliferation index.](1471-2407-12-56-4){#F4}

![**(A) Apoptosis assay at 72 h after FGF19 recombinant protein treatment**. (left) 5-FU treatment; (right) 5-FU and recombinant protein treatment. The apoptosis index (AI) was defined as the OD values of cells treated with these agents divided by those of untreated cells. (**B**) (upper) Invasion assay after FGF19 recombinant protein treatment (100× magnification). (lower) Invasion assay 48 h after FGF19 recombinant protein treatment after FGF19 recombinant protein treatment. (**C**) FGF19 enhanced cell migration ability in JHH7 cell line. The transwell system was used to evaluate migratory ability. Migrated cells were counted and the quantitative results are shown (n = 6). The data presented are from a representative experiment, being quantitatively similar in the replicate experiments.](1471-2407-12-56-5){#F5}

Proliferation and apoptosis assay after FGF19 and FGFR4 siRNA
-------------------------------------------------------------

We selected the JHH7 cell line for further studies because this HCC line showed the highest *FGF19*expression at both the mRNA and protein levels in the 10 HCC lines examined. Transfection of *FGF19*siRNA decreased *FGF19*mRNA expression by 72% after 48 h as compared with cells transfected with control siRNA (Figure [6](#F6){ref-type="fig"}A). Maximum downregulation of FGF19 protein occurred at 72 h after transfection. The FGF19 protein was downregulated by more than 90% in the JHH7 cells (Figure [6](#F6){ref-type="fig"}B). Similarly, *FGFR4*siRNA transfection downregulated mRNA (Figure [6](#F6){ref-type="fig"}C) and protein expression of FGFR4 (Figure [6](#F6){ref-type="fig"}D). Further, proliferation of JHH7 cells was significantly suppressed by *FGF19*siRNA transfection (Figure [6](#F6){ref-type="fig"}E; *n*= 12, *P*\< 0.05) and *FGFR4*siRNA transfection (*n*= 12, *P*\< 0.05). We also found that apoptosis induced by 5-FU increased significantly in the *FGF19*siRNA group at 96 h after transfection (Figure [6](#F6){ref-type="fig"}F; *n*= 12, *P*\< 0.05) and *FGFR4*siRNA transfection (*n*= 12, *P*\< 0.05).

![**Suppression of FGF19 expression was confirmed at transcript level by RT-PCR**. **(A)**and at protein level by ELISA analysis **(B)**. Analysis was performed at 48 h and 72 h following siRNA transfection for mRNA and protein level, respectively. *FGF19*mRNA expression was suppressed to 30% of control siRNA in *FGF19*-specific siRNA-treated cells. n = 12, P \< 0.05 at top of the Figure 6A, 6B, and 6C (like figure 6E and 6D). *FGFR4*gene silencing by siRNA. Suppression of *FGFR4*expression was confirmed at transcript level by RT-PCR (**C**) and at protein level by flow cytometry (**D**). Analysis was performed at 48 h and 72 h following siRNA transfection for mRNA and protein levels, respectively. *FGFR4*mRNA expression was suppressed to 40% of control siRNA in *FGFR4*-specific siRNA-treated cells. n = 12, P \< 0.05 at top of the Figure 6A, 6B, and 6C (like figure 6E and 6D). (**E**) Proliferation assay in JHH7 cells at 72 h after *FGF19/FGFR4*siRNA treatment. (**F**) Apoptosis assay in JHH7 cells at 96 h after *FGF19/FGFR4*siRNA treatment. PI, Proliferation Index. AI, Apoptosis Index.](1471-2407-12-56-6){#F6}

Changes in serum FGF19 level in patients with HCC after hepatectomy
-------------------------------------------------------------------

Serum FGF19 levels were measured at the pre- and postoperative period. Serum FGF19 levels of 10 normal subject were also measured. Postoperative FGF19 levels were significantly lower than those in the preoperative period (Figure [7](#F7){ref-type="fig"}; *n*= 29, *P*\< 0.05). Moreover, FGF19 levels in the normal subjects were significantly lower than those in the preoperative period and significantly higher than those in the postoperative period (Figure [7](#F7){ref-type="fig"}, *P*\< 0.05).

![**The changes in serum FGF19 levels, as measured by ELISA, of the 29 patients with HCCs from 1^st^day and the 8^th^day after curative resection surgery**. Normal shows serum FGF19 levels of the 10 health subjects.](1471-2407-12-56-7){#F7}

Discussion
==========

In this study, we clarified the association between the FGF19/FGFR4 system and the development of HCC using human samples and *in vitro*experimental models. *FGF19*was expressed at significantly higher levels in HCCs, whereas the receptor *FGFR4*was expressed in noncancerous tissue and HCC at similar levels. Han Kiat Ho et al., reported that one third of HCC patients exhibited increased FGFR4 mRNA expression in the matched tumor/normal tissue \[[@B29]\]. In our study, FGFR4 mRNA expression showed no significant difference but increased tendency (Figure [1](#F1){ref-type="fig"}B, *P*= 0.055) in cancer tissue compared with adjacent tissue. Therefore we believe that there is no confliction between the both reports. Further, serum FGF19 significantly decreased after curative hepatectomy. Therefore, FGF19 appears to function in an autocrine or paracrine fashion. *FGF19*mRNA expression was correlated with prognostic significance for the survival of patients with HCC. Thus, this is the first report showing the clinical importance of FGF19. These *in vitro*studies revealed that recombinant FGF19 could induce proliferation, stimulate invasion, and inhibit apoptosis in HCC lines. Inversely, the introduction of *FGF19*and *FGFR4*siRNA was able to reduce proliferation and increase apoptosis in HCC lines. These findings suggest that the FGF19/FGFR4 system plays a critical role in HCC progression.

The mRNA expression levels of *FGF19*and *FGFR4*in HCC have been shown as 46% and 60%, respectively, by *in situ*hybridization \[[@B28]\]. In our study, all the examined human samples expressed both *FGF19*and *FGFR4*mRNA and the corresponding proteins. Further, all the cell lines examined expressed both *FGF19*and *FGFR4*at the higher level than normal hepatocyte. These results suggest that FGF19/FGFR4 are generally expressed in HCC. We investigated the correlation between *FGF19*expression and the clinicopathological parameters in HCC. Our data indicated significant correlation in our cohort between *FGF19*expression and pathological stage. The reason why *FGF19*had no significant correlation with other prognostic factors, such as tumor size and vessel invasion, may be the small number of samples included in this study. Univariate and multivariate analyses revealed FGF19 to be an independent prognostic factor in HCC patients. These results indicate that high levels of FGF19 might help to identify HCC patients with poor prognoses and that FGF19 could be a novel prognostic marker of HCC. However, the detailed mechanism by which high levels of FGF19 contributes to the poor prognosis of patients with HCC must be elucidated by further study. However, we consider that FGF19 is certainly involved in the progression of HCC because recombinant protein and siRNA transfection were capable of affecting proliferation, invasion, and apoptosis in the experimental models.

Previous multivariate analyses have identified several variables as independent predictors of patient prognosis (tumor size, number of lesions, portal vein invasion, etc.) in patients who were not treated surgically and in those who underwent surgical resection. Further, a number of molecular markers with prognostic significance have been identified in HCC \[[@B32]\]. In this study, we showed that FGF19 is a novel independent prognostic factor for both disease-free and overall survival (Table [3](#T3){ref-type="table"}). Moreover, serum FGF19 levels significantly decreased in HCC patients after curative operations (Figure [7](#F7){ref-type="fig"}). The sensitivity of serum FGF19 renders it a promising tumor marker for HCC. These results strongly indicate that FGF19 in surgically excised HCC tissues or preoperatively in the blood serum might help to identify patients with aggressive disease who will need adjuvant therapy.

In this study, we examined whether the introduction of siRNA into HCC cell lines could suppress the proliferative and anti-apoptotic properties of the HCC cell lines *in vitro. FGF19*siRNA successfully suppressed *FGF19*mRNA and FGF19 protein expression in the high FGF19-expressing cell line JHH7. Further, the proliferative and anti-apoptotic properties of JHH7 were lost *in vitro*after FGF19 siRNA transfection. Transfection of *FGFR4*siRNA showed similar results. Recently, Desnoyers et al. have reported that neutralizing antibody of FGF19 treatment significantly suppressed the growth of established colon cancer tumors *in vivo*\[[@B28]\]. RNAi has been effectively used in target-directed therapies in a range of diseases and in the silencing of tumor genes by systemically administered siRNA *in vivo*\[[@B33]-[@B35]\]. Likewise, with antibody treatment, *FGF19*and *FGFR4*siRNA also may be potential targets for systemic therapy for HCC.

Conclusions
===========

In conclusion, our results demonstrated that FGF19 expression was significantly upregulated in HCCs, with higher expression being correlated with poor prognosis. Our results raise the possibility for potential treatment strategies aimed at functional abrogation of *FGF19*that provide new therapeutic approaches in the management of HCC.
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